Trial Profile

A Pivotal Study to Evaluate Socazolimab for Recurrent or Metastatic Cervical Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Nov 2021 According to a Sorrento Therapeutics media release, the company's license partner, China Oncology Focus Limited (COF) Lee's Pharmaceutical, has submitted a NDA (new drug application) for Socazolimab for the greater China territory to treat recurrent or metastatic cervical cancer. The NDA application has been accepted by China NMPA.
12 Mar 2021 New trial record
07 Mar 2021 According to a Sorrento Therapeutics media release, Lees Pharm expects to file the New Drug Application for Socazolimab in recurrent or metastatic cervical cancer in the second quarter of 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com